Recent approaches for control of *E. coli* and respiratory complex in Middle East

Hussein M. Galal a, Azza M. Tawfek b, Mohamed I. Abd Rabou c, Ashgan Mohamed Hessain d,*
Jwaheer Haji Alhaaji e, Saleh A. Kabli f, Ayman Elbehiry g, Waleed K. Alwarhi h, Ihab M. Moussa i,*

aDepartment of Microbiology, Faculty of Veterinary Medicine, Cairo University, Giza, Egypt
bDepartment of Clinical Pathology, Faculty of Veterinary Medicine, Cairo University, Giza, Egypt
cDepartment of Cytology and Histology, Faculty of Veterinary Medicine, Cairo University, Giza, Egypt
dDepartment of Health Science, College of Applied Studies and Community Service, King Saud University, Saudi Arabia
eDepartment of Biology, Faculty of Science, King Abdulaziz University, P.O. Box 80203, Jeddah, Saudi Arabia
fDepartment of Bacteriology, Mycology and Immunology, Faculty of Veterinary Medicine, University of Sadat City, Egypt
gDepartment of Botany and Microbiology, College of Science, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia

**A R T I C L E I N F O**

Article history:
Received 14 December 2017
Revised 26 March 2018
Accepted 1 April 2018
Available online 3 April 2018

Keywords:
Colibacillosis
Poulvac *E. coli* vaccine
IBV variant 02

**A B S T R A C T**

This study was conducted on 100 one-day-old broiler chicks to evaluate the effect of Poulvac *E. coli* vaccine in reduction of clinical signs and complications after concurrent infectious bronchitis virus (variant 02) and virulent *E. coli* O78 challenges. The birds were evaluated for clinical signs, mortality for 7 days post-infection, PM lesion score, average body weight and serological evaluation. Re-isolation and RT-PCR for the challenging infectious bronchitis virus (IBV) variant 02 were conducted thereafter. The results showed that the Poulvac *E. coli* at one-day old chicks in the presence of co-infection with virulent *E. coli* and IBV variant 02 provides better body weight gain at 35 days than the other groups. The challenge with IBV variant 02 alone in non-vaccinated birds doesn’t give any mortality; this indicated that the severity of IBV variant 02 increased by the presence of co-infection with Avian Pathogenic *E. coli* (APEC). The mortality percentage associated with both *E. coli* and IBV variant 02 infections in the non-vaccinated group by Poulvac *E. coli* was 25% while this percentage was 10% of the vaccinated group. The Poulvac *E. coli* is not negatively affecting the immune response against different concurrent viral vaccines like Infectious bursal disease (IBD), and moreover, it improves the immune response against some others like Newcastle disease virus (NDV), Avian Influenza (A) H5 and IBV.

© 2018 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Broiler industry is facing several challenges from viral and bacterial infections; the most common in the Middle East (ME) is the Respiratory Complex Syndrome, where APEC plays an important role in the severity of this syndrome. Morbidity of IBV has been almost always 100%, but mortality can vary between 0% and 82%, depending on the age and the immune status of the birds, the strain of the virus, and if secondary bacterial or viral pathogens are involved (Jackwood and De wit, 2013). Mixed infection of avian respiratory viruses, including IBV may induce similar clinical signs/lesions and thus complicate diagnostic decisions (Nguyen et al., 2013), as well as complicating its control.

Viral infections of the respiratory tract, such as IBV infection, facilitate the pathway of both colibacillosis of the respiratory tract and systemic colibacillosis (Nakamura et al., 1992; Peighambari et al., 2002; Matthijs et al., 2005) and thus resulting in increased severity and mortality associated with the disease. The mechanisms behind enhanced susceptibility to bacterial super-infection after viral infection have been studied extensively, but are still not well understood. A first set of hypotheses suggests increased susceptibility due to tissue damage in the respiratory tract resulting in functional impairment. Three possible causes have been described as mechanisms for functional damage. Viral replication in the upper respiratory tract causes loss of cilia and ciliated cells...
(Bakalitz, 1995), decreased ciliary activity impairs mucociliary clearance (Wilson et al., 1996) and finally, damage to epithelium may provide more attachment sites for bacteria (El Ahmer et al., 1999). A second set of hypotheses suggests altered innate immune responses. Impairment of innate effector functions, i.e. adhesion and entry, phagocytosis, killing, nitric oxide (NO) and superoxide production (Ariaans et al., 2008). So this study came as a response to evaluate the effect of the commercially available Poulvac E. coli vaccine in reduction of complications and clinical signs associated with IBV variant 02 infection and to evaluate the effect of the vaccine on the immune response of concurrent viral vaccines being used in broilers.

2. Materials and methods

2.1. Experimental chickens

One hundred of one-day old broiler chicks were floor reared under strict hygienic condition, in a previously cleaned and disinfected experimental unit. The chicks were provided with commercial broiler ration, water and feed were provided ad libidum. The chicks were Vaccinated with the common vaccination program applied in the ME; all chicks were vaccinated at day old with inactivated H5N1 reassortant vaccine (Egyflu prepared from A/ch/EGyp/A-18-H-09 strain, Harbin weike biotechnology CO., China.), and inactivated oil emulsion NDV-vaccine (OL-VAC, prepared from La Sota strain, FATRO CO., Italy), Poulvac IB primer and Poulvac NDW (Zoetis) were applied by coarse spray. At 14 days old birds were Vaccinated with Nobilis, Ma5 + Clone 30 (MSD), for control of IB, Bursine2 (Zoetis) was applied in drinking water at 8 and 16-day old. The chicks were divided into 5 groups (20 each) according to Poulvac E. coli vaccination scheme and APEC and IBV variant 02 challenges (Table 1).

2.2. Challenging virus and bacteria

The IBV variant 02 strain used in the challenge was obtained from (MEVAC company for vaccine production, Egypt), (EG/1212B, accession no. JQ839287.1). While the strain of Avian pathogenic E. coli O78 was isolated from outbreaks of colibacillosis, O78 challenges.

2.3. Clinical examination and necropsy

All chicks in the different experimental groups were observed for clinical signs of IBV and colibacillosis. PM examination was done according to the established system outlined by Peighambari et al. (2002) with recordings of the characteristic lesions for IBV/colibacillosis infection, including mucosal thickening with serous or catarrhal exudates in the nasal passage, sinuses and trachea. Presence of cloudy air sacs, which may contain caseous exudates, caseous material in the abdominal cavity, swollen and pale kidneys, with tubules and ureters distended with urates.

2.4. Antigens

The heterologous antigen of inactivated H5N2 Influenza vaccine (A/chicken/Mexico/232/94(CPA) was used in the Haemagglutination (HA) & Haemagglutination Inhibition (HI) test to evaluate the antibody titers for AI H5 while Live la Sota vaccine titered and used as antigen for HA& HI to evaluate the antibody titers for NDV.

2.5. Blood samples

Chicken blood samples were collected from wing vein or by slaughtering and kept in slop position at 37 °C for one hour then at 4 °C overnight. Sera then separated by centrifugation at 3000 rpm/10 min and stored at −20 °C till tested, sera were used for detection of specific IBV. IBD antibodies using ELISA (Symbiotic) and specific H5N1 and NDV antibodies using HI test according to OIE (OIE terrestrial manual, 2008).

2.6. RT-PCR for IBV variant 02 S1 gene

The RT-PCR was carried out the 3 days post challenge on tracheas, 5 and 7 days post challenges on kidneys for detection of IBV (variant 02), according to the manufacturer’s instructions using reagents provided in the kits: Thermo scientific. The amplified region of the RNA of the IBV (variant 02) was analyzed by gel electrophoresis according to Adzhar et al. (1997).

2.7. Sequencing of the amplified part of the IBV S1 gene

The RT-PCR product of positive samples were sent to (lab technology) for sequencing the amplified part (464 bp) of the S1 gene. Sequence chromatograms are edited using Mega 5 software. Edited sequences of IBV isolates were characterized using BLASTn for nucleotide or BLASTp for protein analysis (http://www.ncbi.nlm.nih.gov/BLAST/) (OIE Terrestrial Manual, 2013).

3. Results

3.1. Clinical signs

The clinical signs observed after IBV challenge were mild respiratory manifestations (ruffled feathers, rales, gasping, nasal discharge and diarrhea). The severity was increased in the groups challenged by Avian Pathogenic E. coli 3 days post challenge, Table 1

| Group no. | Chick no. | Vaccination (Age/day) | Challenge (Age/day) |
|-----------|-----------|-----------------------|---------------------|
|           | IBV       | Poulvac E. coli       | IBV                 | E. coli |
| 1         | 20        | 1 * 14                | 1                   | 25      | 28 |
| 2         | 20        | 1 * 14                | –                   | 25      | 28 |
| 3         | 20        | –                     | –                   | 25      | –  |
| 4         | 20        | 1 * 14                | –                   | –       | –  |
| 5         | 20        | –                     | –                   | –       | –  |

a. IBV vaccination dose at 1-day old by coarse spray (Poulvac IB primer) & at 14 days (Ma5) according to the company instructions.
b. E. coli vaccination dose at 1-day old by coarse spray with Poulvac E. coli according to the company instructions.
c. IBV challenge virus. Oculonasal challenge at 25 day of age with 100 μl/bird from 10^6.5 EID50 per ml of IBV variant 2.
d. E. coli challenge bacteria. Intratracheal challenge at 28 day of age with 1 ml/bird 10^8 CFU per ml E. coli O78.

H.M. Galal et al. / Saudi Journal of Biological Sciences 25 (2018) 1302–1307 1303
especially the enteric signs while the non-challenged groups were apparently healthy.

3.2. Average body weight

The average body weight was evaluated at the 23, 30 and 35 days of age. In the 1st group was 1.3 kg, 2.04 kg and 2.26 kg, respectively, while in the 2nd group 1.3 kg, 1.83 kg and 2.14 kg, respectively, and in the 3rd group 1.11 kg, 1.7 kg and 2 kg, respectively, in the 4th group 1.33 kg, 1.88 kg and 2.1 kg, respectively, and the 5th group 1.1 kg, 1.92 kg and 2.2 kg, respectively.

3.3. Mortality and PM lesions

Mortalities were observed for one week after E. coli challenge. The mortality percentage were negative in non-challenged groups or group challenged with IBV only, but mortalities were 10% in the 1st group (vaccinated with IBV vaccines and Poulvac E. coli and challenged by IBV (variant 02) and Avian pathogenic E. coli O 78 and 25% in the 2nd group (vaccinated with IBV vaccines only and challenged with IBV (variant 02) and E. coli O 78 as shown in (Table 2). The P.M lesions score included cloudiness, turbidity or deposition of fibrinic membrane on the liver, heart and air sacs for E. coli challenged groups were 3 and 3.2 in the 1st group (vaccinated by IBV and E. coli and challenged by IBV and E. coli) and the 2nd group (vaccinated by IBV and challenged by IBV and E. coli), respectively, as shown in Table 2.

3.4. Serological evaluation of antibody titers for AI H5 and ND by HI

The antibody titers against avian influenza H5N1 virus was evaluated at 21, 27 and 37 days of age. The HI titer (log$_2$) for the 1st group was 3.2, 5.7 and 6.2, respectively, in the 2nd group was 4, 5.5 and 5.2, respectively, for the 3rd group, this titer was 4, 4.2 and 5.7, respectively, for the 4th group 4.5 and 6, respectively, and the 5th group 4.5 and 5.7, respectively. The antibody titers against NDV were evaluated at 21, 27 and 37 days of age. The HI titer (log 2) for the 1st group was 5.2, 5.7 and 6.2, respectively, for the 2nd group was 3.5, 5.5 and 5.2 respectively, for the 3rd group was 6, 5.7 and 6 respectively, the 4th group was 3.5,

5.5 and 5.7 respectively, the 5th group was 6, 5.7 and 5.2 respectively (Table 3 and Figs. 1 and 2).

3.5. Serological evaluation of antibody titers for IB and IBD by ELISA

The antibody titers against IBV evaluated by ELISA at 21, 27 and 37 days of age, and the result showed that the antibody titer for the 1st group was 860 ± 97 and 517 ± 229 at 27 and 37 days respectively, for 2nd was 574 ± 204, 417 ± 117 and 1095 ± 983, respectively, but, the 3rd group was 433 ± 73 and 2160 ± 1536, respectively. Antibody titers against IBDV were evaluated by ELISA at 21, 27 and 37 days of age, for the 1st group was 4162 ± 1172 and 2978 ± 581 at 27 and 37 days respectively, for the 2nd was 4204 ± 746, 3039 ± 850 and 3486 ± 427, respectively, for the 3rd group was 2864 ± 604 and 4145 ± 656 at 27 and 37 days, respectively, for the 4th group was 3486 ± 637 and 4145 ± 656 at 27 and 37 days of age, respectively (Table 4).

3.6. Results for re-isolation of IBV var 2 and E. coli post challenge

Avian Pathogenic E. coli was re-isolated according to Murray et al. (19), 3 and 5 days post challenge from the heart, blood, liver

---

**Table 2**

| Group no. | Chick no. | Vaccination age/day | Challenge Age/day | BW ratio Age/day | Mortality % | PM lesion score |
|-----------|-----------|---------------------|-------------------|------------------|-------------|----------------|
|           |           | Poulvac E. coli     | IBV               | IBV E. coli      |             |                |
|           |           | 23                  | 30                | 35               |             |                |
| 1         | 20        | 1                   | 1 + 14            | 25               | 1.334       | 2.04           | 2.26           | 10             | 3             |
| 2         | 20        | –                   | 1 + 14            | 25               | 1.334       | 1.83           | 2.14           | 25             | 3.2           |
| 3         | 20        | –                   | –                 | 25               | 1.105       | 1.7            | 2              | 0              | ND            |
| 4         | 20        | –                   | –                 | 1 + 14           | 1.334       | 1.88           | 2.1            | 0              | ND            |
| 5         | 20        | –                   | –                 | –                | 1.105       | 1.92           | 2.2            | 0              | ND            |

**Table 3**

The results of HI for (AI H5 and NDV) for different experimental groups at different ages.

| Group no. | Chick no. | HI Titer (log 2) GM age/day | NDV |
|-----------|-----------|-----------------------------|-----|
|           |           | AI H5 21 27 37              |     |
| 1         | 20        | 3.2 5.7                      | 5.2 5.7 6.2 |
| 2         | 20        | 4 5.5 5.2                    | 3.5 5.5 5.2 |
| 3         | 20        | 4 4.2 5.7                    | 6 5.7 6    |
| 4         | 20        | 4 5.7                        | 3.5 5.5 5.7 |
| 5         | 20        | 4 5                          | 6 5.7 5.2 |

---

Fig. 1. HI Titer for AI H5 (log 2 GM) for different experimental groups at different ages.
parenchyma, air sacs and gall bladder in E. coli challenged groups and then the colonies tested for agglutination against O-78 specific antisera and all groups were positive for this strain. Re-isolation of IBV was performed from trachea 3-day post challenge and kidneys 5 and 7 days post challenge by intrallantoic inoculation in 9–11 days SPF eggs, the allantoic fluid was collected after 48 h from inoculation and examined by RT-PCR, all samples from all groups were RT-PCR positive (Table 5).

4. Discussion

Many viral and bacterial diseases are affecting the broiler industry in Middle East causing severe economic losses by billions of dollars per year. Poultry meat represents more than 70% from protein eaten by humans, so controlling such diseases and minimizing the mortality rates is very essential to save both the human and animal health (FAO, 2002). It is commonly believed that in broiler chickens maintained under commercial conditions the lesions caused by the IBV are sufficiently severe to permit E. coli to invade the affected tissues and give rise to generalized infection and often with high mortality. There is an evidence to support this view in that a condition resembling the natural disease can be produced by inoculating chickens with a mixture of IBV and E. coli (Smith et al., 1985).

In this study 100 one-day old broiler chicks were floor reared under strict hygienic condition, divided into 5 groups (20 chicks each) for studying the effect of virulent E. coli challenge in the severity of IBV infection and the role of Poulvac E. Coli in reduction of the severity of IBV disease, especially that is caused by IBV variant 02 which is endemic in ME. The chicks in experimental group 1 were vaccinated with Poulvac E. coli vaccine and commercially

Table 4

The results of ELISA titers for IBV and IBD for different experimental groups at different ages.

| Group no. | Vaccination age/day | Challenge age/day | ELISA Titer mean ± SD |
|-----------|---------------------|-------------------|-----------------------|
|           | Poulvac E. coli | IBV | IBV | E. coli | IBV | IBV | E. coli | IBV | IBV | E. coli | IBV | IBV | E. coli |
| 1         | 1                   | 21   | 27  | 37     | 860 ± 97 | 517 ± 229 | ND | 4162 ± 1172 | 2978 ± 581 |
| 2         | –                   | 21   | 27  | 37     | 574 ± 204 | 417 ± 117 | 1095 ± 983 | 4204 ± 746 | 3039 ± 850 | 3486 ± 427 |
| 3         | –                   | –    | 25  | –      | 574 ± 204 | 433 ± 73  | 2160 ± 1733 | ND | 2864 ± 604 | 4145 ± 561 |
| 4         | –                   | 1 + 14| –   | –      | 596 ± 228 | 1520 ± 1536 | 4204 ± 746 | 4311 ± 502 | 2464 ± 785 |

Table 5

Results of RT-PCR for IBV Variant 02.

| Group no. | Vaccination age/day | Challenge age/day | IBV RT-PCR |
|-----------|---------------------|-------------------|-------------|
|           | Poulvac E. coli | IBV | IBV | E. coli | Trachea 3 days post challenge | Kidney | 5 days post challenge | 5 days post challenge |
| 1         | 1                   | 1 + 14 | 25  | 28     | +                       | +         | +           | +           |
| 2         | –                   | 1 + 14 | 25  | 28     | +                       | +         | +           | +           |
| 3         | –                   | –     | 25  | –      | +                       | +         | +           | +           |
| 4         | –                   | 1 + 14 | –   | –      | ND*                     | ND         | ND           | ND           |
| 5         | –                   | –     | –   | –      | ND                      | ND         | ND           | ND           |

* Not detected.
available IBV vaccines and challenged for both virulent *E. coli* O78 and IBV variant 02, while those in group 2 were vaccinated with commercially available IBV vaccines and challenged by both virulent *E. coli* O78 and IBV variant 02. Chicks in group 3 were not vaccinated while challenging by IBV variant 02 only. Chicks in group 4 were vaccinated with IBV only. Chicks in group 5 were neither vaccinated nor challenged. In the present study the effect of Poulvac *E. coli* in reduction of the severity of the co-infection of IBV and *E. coli* was evaluated on the basis of average body weight, mortality, PM lesion scoring, serology, clinical signs, histopathology and re-isolation of both *E. coli* and IBV.

The clinical signs observed after IBV variant 02 challenges were a mild respiratory manifestation (ruffled feathers, rules, gasping, nasal discharge and diarrhea) the severity were increased in the groups challenged with *E. coli* O78 3 days post challenge, especially the enteric signs, while non challenged groups were apparently healthy, these results are going in harmony with that of Smith et al. (1985). The previously mentioned results indicated that challenge with IBV variant 02 gave very mild disease reflected on the percentage of mortality which was clear in the group 3, non-challenged by *E. coli* O78 (0% Mortality). On the other hand, the mortality in groups co-challenged with *E. coli* O78 and IBV variant 02 varied according to the administration of Poulvac *E. coli* vaccine (10% in vaccinated group and 25% in non-vaccinated group) and these results were in agreement with the data mentioned by Jackwood (2012). The average body weight for the group 1, 2, 3, 4 and 5 were at 35 days old 2.26, 2.14, 2, 2.1 and 2.2 kg respectively. The results indicated that the vaccination against *E. coli* using Poulvac *E. coli* could reduce the effect of the challenge or natural infection occurred by Avian Pathogenic *E. coli* on average body weight as previously reported by La Ragione et al. (2013). The PM lesions score included cloudiness, turbidity or deposition of fibrinotic membrane on the liver, heart and air sacs for Avian Pathogenic *E. coli* challenged groups were 3 and 3.2 in groups 1 and 2 respectively. The reduction of the lesion score might be due to the protective effect of Poulvac *E. coli* vaccination at day old, these findings are supported by that reported by La Ragione et al. (2013). The effect of Poulvac *E. coli* on the immune response to concurrent vaccination against AI H5, NDV, IBV and IBD have been evaluated through detection of the antibody titers at different ages against each particular agent by the standard serological tests. The serological evaluation for both AI H5 and NDV revealed that the HI titer (log 2) for the groups 1, 2, 3, 4 and 5 were at 37-day old for AI H5 6.2, 5.2, 5.7, 6 and 5.7 respectively and for NDV were 6.2, 5.2, 6, 5.7 and 5.2, respectively. Our reading of these results indicates that the application of Poulvac *E. coli* at day old concurrantly with oily AI H5 + NDV vaccine and live NDV vaccine is not affecting the immune response to these vaccines, moreover, it showed improvement in the immune responses as it's clear in group 1 (vaccinated and challenged), these results are reported as well by Tobias et al. (2013). The ELISA antibody titer for IBV at 37 days were 517 ± 229, 1095 ± 93, 2160 ± 733 and 1520 ± 153 in groups 1, 2, 3 and 4 respectively, the significant differences in the antibody titers in the different groups are due to the effect of vaccinations/challenges differences. The high antibody titer in group 3 is resulted from challenging with IBV variant 02 in non IBV vaccinated birds. The application of Poulvac *E. coli* at day old improves the immune response against IBV challenge and this was clear in group 1 where we did not observe an increase in the antibody titers like that observed clearly in group 3, these results are closely similar to that reported in De wit et al. (1998, 2010). The ELISA antibody titers for IBD at 37 days were 2978 ± 581, 507 ± 178, 4145 ± 561 and 2464 ± 785 in groups 1, 2, 3, and 4 respectively. Poulvac *E. coli* vaccine improves the early immune response at 27 days old for IBDV 4182+ than the non-vaccinated group 2 while no significant differences observed between the all different groups at 37 days. Our readings indicate that the vaccine is not negatively affecting the immune response to IBD vaccination; these results were in agreement also with that mentioned in De wit et al. (1998, 2010) and Tobias et al. (2013).

5. Conclusions

It’s concluded that Poulvac *E. coli* at day old aid in reduction of mortality from 25% to 10% in groups challenged by virulent *E. coli* O78 and IBV variant 02 strain, Poulvac *E. coli* at one-day old together with IB primer at day old in the presence of co-infection with virulent *E. coli* and IBV variant 02 (group 1) provide better BW gain at 35 days than the all other non-vaccinated groups. The challenge with IB variant 02 alone in non-vaccinated birds didn’t give any mortality (group 3); this indicated that the severity of IBV variant 02 is being increased by the presence of co-infection with APEC O78. Poulvac *E. coli* at day old is not negatively impacting the immune response to concurrently applied vaccines for AI H5, NDV, IBV and IBD and moreover improves the immune response even better than the non-vaccinated non challenged groups. Difference of epidemiological data between countries in poultry production industry requires efforts to position any veterinary drug or vaccine in a way to get the best effective results in terms of high body weight and low mortality rate, which will reflect on the animal health and consequently the human health.

Acknowledgment

The authors extend their appreciation to the Deanship of Scientific Research at King Saud University for funding the work through the research group project No.: RG-162.

References

Adzhar, A., Gough, R.E., Haydon, D., Shaw, K.K., Britton, P., Cavanagh, D., 1997. Molecular analysis of the 793/B serotype of infectious bronchitis virus in Great Britain. Avian Path. 26, 625–640.
Ariaans, M.P., van de Haar, P.M., Lowenthal, J.W., van Eden, W., Hensen, E.J., Vervelde, L., 2008. ELISPOT and intracellular cytokine staining: novel assays for quantifying T cell responses in the chicken. Dev. Comp. Immunol. 32 (11), 1398–1404.
Bakaletz, L.O., 1995. Viral potentiation of bacterial superinfection of the respiratory tract. Trends Microbiol. 3, 110–114.
De Wit, J.J., Melks, D.R., Koch, G., Westenbrink, F., 1998. Detection of specific IgM antibodies to infectious bronchitis virus by an antibody-Capture ELISA. Avian Path. 27, 155–160.
De Wit, J.J., Swart, W.A., Fabri, T.H., 2010. Efficacy of infectious bronchitis virus vaccinations in the field: association between the -IBV IgM response, protection and vaccine application parameters. Avian Path. 39, 123–213.
El Ahmmer, O.R., Raza, M.W., Goglivie, M.M., Weir, D.M., Blackwell, C.C., 1999. Binding of bacteria to HEP-2 cells infected with influenza A virus. FEMS Immunol. Med. Mic. 23, 331–341.
FAO, 2002. Practical production of protein for food animals.
Jackwood, M.W., 2012. Review of Infectious Bronchitis Virus around the World. Avian Dis. 56, 634–641.
Jackwood, M.W., De wit, S., 2013. Diseases of poultry. 13th Edition David Swayne, pp. 139–159.
La Ragione, R.M., Woodward, M.J., Kumar, M., Rodenberg, J., Fan, J., Hayes, A.D., Karaca, K., 2013. Efficacy of a live attenuated Escherichia coli O78:K80 vaccine in chickens and turkeys. Avian Dis. 57 (2), 273–279.
Matthys, M.G.C., van Eck, J.H., de Wit, J.J., Bounia, A., Stegeman, J.A., 2005. Effect of IBV-H120 vaccination in broilers on colibacillosis susceptibility after infection with a virulent Massachusetts-type IBV strain. Avian Dis. 49, 540–545.
Nakamura, K., Cook, J.K.A., Olsuki, K., Huggins, M.B., Fraizer, J.A., 1992. Comparative study of respiratory lesions in two chicken lines of susceptibility, infected with infectious bronchitis virus: histology, ultrastructure and immunohistochemistry. Avian Path. 20, 245–261.
Nguyen, T.T., Kwon, H.J., Kim, H.L., Hong, S.M., Seong, W.J., Jang, J.W., Kim, J.H., 2013. Multiplex nested RT-PCR for detecting avian influenza virus, infectious bronchitis virus and Newcastle disease virus. J. Virol. Methods 188 (1–2), 41–46.
OIE terrestrial manual, 2008. OIE Manual of Diagnostic tests and vaccines for terrestrial animals.
OIE Terrestrial Manual, 2013. OIE Manual of Diagnostic tests and vaccines for terrestrial animals (chapter 102).
Peighambari, S.M., Hunter, D.B., Shewen, P.E., Gyles, C.L., 2002. Safety, immunogenicity, and efficacy of two Escherichia coli cya crp mutants as vaccines for broilers. Avian Dis. 46, 287–297.

Smith, H.W., Cook, J.K., Parsell, Z.E., 1985. The experimental infection of chickens with mixtures of infectious bronchitis virus and Escherichia coli. J. Gen. Virol. 66, 777–786.

Tobias, F.F., Celso, F.J., Max, I., Breno, C.B., Alberto, I., Ludio, G., Luiz, F., 2013. Effect of spray Escherichia coli vaccine on the immunity of Poultry. Avian Dis. 57, 671–676.

Wilson, R., Dowling, F.J., Jackson, A.D., 1996. The biology of bacterial colonization and invasion of the respiratory mucosa. Eur. Respir. J. 9 (7), 1523–1530.